Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY antibody persistence study in South Korean children after 4-dose infant vaccination
2014-005392-90Phase 4
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Meningococcal groups A, C, W, and Y oligosaccharide diphtheria CRM-197 conjugate vaccine in meningococcal disease, sponsored by Novartis. Primary endpoint: Percentage of subjects with hSBA >= 8 at Visit 6.
02
Drugs
Meningococcal groups A, C, W, and Y oligosaccharide diphtheria CRM-197 conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-005392-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005392-90.